Publications

1 February

Working Paper 6 – The Role of Health Technology Assessment in Medicine Pricing and Reimbursement

1 February

Policy Brief 1 – External Reference Pricing

1 February

Working Paper 2 – The Role of Health Insurance in the Cost-Effective Use of Medicines

1 February

Working Paper 5 – Sales Taxes on Medicines

1 February

Working Paper 3: The Regulation of Mark-ups in the Pharmaceutical Supply Chain

1 January

Understanding and Responding To Medicines Promotion

1 December

The Status Quo Wins Again: Selected R&D Demonstration Projects Disappoint, Offer Little Progress (2013)

11 October

EU Regulation on Clinical Trials: Further enhance clinical data transparency

6 October

Transparency of Clinical Trial Data on Medicines in the EU

27 September

Transparency in the Public Interest: How the EMA Policy on Publication and Access to Cinical-trial Data Could Help Save Lives

20 September

Trade, TRIPS+, & Access to Medicines

18 September

EU-Thailand Free Trade Agreement: Not at the expense of access to medicines

25 July

HAI Europe Calls on EFPIA and PhRMA to Truly Commit to Clinical Trial Data Transparency

1 July

LAC-Global Alliance Statement on Trans-Pacific Partnership and Access to Affordable Medicines

21 June

NGOs Condemn the EU Press Release on TRIPS Extension for Least Developed Countries

17 June

Long-awaited Steps Towards Affordable Access and Needs-driven Research and Development

16 April

Comprendre la promotion pharmaceutique et y répondre: Un manuel pratique

9 April

EU-India free trade deal puts millions of lives at risk

1 April

La Alianza LAC-Global reconoce el paso dado por el Medicines Patent Pool

1 March

2012 Annual Report

1 March

2012 Financial Statements

28 November

Follow-up on CEWG Report on Research and Development Financing and Coordination 2012

16 July

ACTA is dead, long live ACTA? ACTA-like measures still in EU IP policies

8 June

Time for the final push: Say “No” to ACTA – again

25 May

EU and U.S. Negotiators Block Broad Support of Low- and Middle-income Countries to Move Towards Binding Health and Development R&D Convention

15 May

EU Parliament Says No and No Again to EMA: Independent Groups Echo Decision

18 April

Health Activists and Consumers Ask for Greater Public Return on EU Health R&D Spending and a Turn to Needs-driven Innovation

28 March

Big Pharma Spends Over €40 Million per Year Lobbying in the EU, Dwarfing Public Health NGOs

26 March

Civil Society Calls on Members of the European Parliament to Condemn ACTA

20 March

Divide and Conquer: A look behind the scenes of the EU pharmaceutical industry lobby